Investment Rating - The report maintains a "Buy" rating for Pien Tze Huang (600436.SS) with a 12-month price target of Rmb280, indicating an upside potential of 21.5% from the current price of Rmb230.54 [2][8][7]. Core Insights - Pien Tze Huang reported 3Q24 earnings of Rmb965 million, reflecting a year-on-year increase of 12.0% and a 6.3% beat against Goldman Sachs estimates, attributed to better gross profit margins and lower-than-expected expenses [1][2]. - The revenue for 3Q24 was Rmb2,800 million, marking a 9.6% increase year-on-year and a 2.9% increase compared to Goldman Sachs estimates, driven by strong sales growth in hepatic disease medication, which saw a 25.3% year-on-year increase [2][6]. - The report anticipates a healthy compound annual growth rate (CAGR) in sales and earnings per share (EPS) between FY23 and FY26, supported by ongoing production growth and pricing hikes amid increasing demand [6][7]. Financial Estimates - Earnings estimates for Pien Tze Huang have been revised upwards by 2.8% for 2024E, with net profit expected to reach Rmb3,068 million, a 2.8% increase from previous estimates [4][5]. - Revenue projections for 2024E have been adjusted to Rmb11,135 million, reflecting a 2.3% increase from prior estimates, with EBIT expected to be Rmb3,613 million, a 2.9% increase [4][5]. - The report highlights a stable gross profit margin (GPM) of 46.9% for 3Q24, slightly improved from 46.6% in previous estimates, despite pressures from rising cow bezoar costs [1][2].

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company's revenue for the first three quarters of 2024 reached 8.45 billion yuan, a year-on-year increase of 11.19%, with a net profit attributable to the parent company of 2.687 billion yuan, up 11.73% year-on-year [4] - The core product for liver disease treatment has shown rapid growth, with revenue of 4.283 billion yuan, a year-on-year increase of 20.24% [4] - The company is expanding its distribution channels, with over 100,000 terminal stores covered through strategic partnerships with major chain pharmacies [4] - Profit forecasts for 2024-2026 indicate net profits of 3.148 billion yuan, 3.627 billion yuan, and 4.182 billion yuan, representing year-on-year growth rates of 12.5%, 15.2%, and 15.3% respectively [4] Financial Performance - The company achieved a revenue of 10.058 billion yuan in 2023, with a projected revenue of 11.346 billion yuan in 2024, reflecting a year-on-year growth of 12.8% [5][8] - The gross profit margin is expected to improve from 46.8% in 2023 to 50.0% by 2026 [8] - The net profit margin is projected to be 27.7% in 2024, increasing to 29.8% by 2026 [8] Market Position and Valuation - The company is expected to maintain a price-to-earnings (P/E) ratio of 45-50x for 2024, with a reasonable value range of 234.90 to 261.00 yuan per share [4] - The company’s core product, Pian Zai Huang, is characterized by strong consumer demand and scarcity, contributing to its valuation premium [4] Revenue Breakdown - The pharmaceutical manufacturing segment generated 4.612 billion yuan in revenue, a year-on-year increase of 19.71%, while the pharmaceutical distribution segment saw revenue of 3.153 billion yuan, up 3.08% [4][6] - The cosmetics segment reported revenue of 525 million yuan, reflecting a year-on-year growth of 21.92% [4]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company reported a total revenue of 8.45 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 11.2%. The net profit attributable to the parent company was 2.69 billion yuan, up 11.7% year-on-year [2]. - The company is actively expanding its sales channels and enhancing its product matrix, with significant growth in liver disease medications and cosmetics [2]. - The rise in the price of natural cow bile has pressured gross margins, but potential easing of cost pressures is anticipated due to policy changes allowing imports of cow bile [2]. - The company is investing in innovative research and development, with several new drug projects entering critical research phases [2]. - Profit forecasts for 2024-2026 predict net profits of 3.15 billion yuan, 3.70 billion yuan, and 4.43 billion yuan, with corresponding PE ratios of 46, 39, and 33 times [2]. Summary by Sections Financial Performance - Total revenue for the first three quarters of 2024 was 8.45 billion yuan, a 11.2% increase year-on-year. The net profit attributable to the parent company was 2.69 billion yuan, reflecting an 11.7% increase [2]. - The gross margin for the first three quarters was 45.4%, down 3 percentage points year-on-year, with the pharmaceutical manufacturing gross margin at 66.9%, down 8.4 percentage points [2]. Sales and Market Expansion - The company has upgraded all "Pian Zai Huang Experience Halls" to "Pian Zai Huang National Medicine Halls" to enhance brand image and has partnered with major pharmacy chains, achieving coverage of over 100,000 stores [2]. - Revenue from liver disease medications reached 4.28 billion yuan, up 20.2% year-on-year, while cardiovascular medications generated 270 million yuan, up 11.7% [2]. - The cosmetics segment achieved revenue of 530 million yuan, a 21.9% increase, driven by the development of popular products [2]. Research and Development - The company has received clinical approval for a new drug for lymphoma treatment and is advancing multiple new drug projects in various therapeutic areas [2]. - Ongoing research includes over 30 studies on the efficacy of Pian Zai Huang in treating viral infections and clinical studies for liver cancer [2]. Profit Forecasts - Expected net profits for 2024, 2025, and 2026 are 3.15 billion yuan, 3.70 billion yuan, and 4.43 billion yuan, with PE ratios of 46, 39, and 33 respectively [3].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][7]. Core Insights - The company has shown a recovery in profit growth in Q3 2024, with a year-on-year increase in revenue of 11.19% to 8.45 billion yuan and a net profit increase of 11.73% to 2.687 billion yuan [3][4]. - The gross margin for the liver disease medication remained stable at 68.23%, while the overall gross margin decreased by 4.32% year-on-year to 46.87% [4]. - The establishment of an academic workstation led by a renowned expert signifies a commitment to innovation and collaboration in traditional Chinese medicine [4]. Financial Performance Summary - For the first three quarters of 2024, the company reported: - Revenue: 8.45 billion yuan (yoy +11.19%) - Net profit: 2.687 billion yuan (yoy +11.73%) - Non-recurring net profit: 2.715 billion yuan (yoy +11.25%) [3][4]. - In Q3 2024 alone: - Revenue: 2.8 billion yuan (yoy +9.60%) - Net profit: 965 million yuan (yoy +11.73%) - Non-recurring net profit: 964 million yuan (yoy +11.66%) [3][4]. Market Performance - The company's stock performance over different time frames: - 1 Month: +20.4% - 3 Months: +4.7% - 12 Months: +2.2% - Compared to the CSI 300 index, which had returns of +22.9% (1M), +11.2% (3M), and +12.1% (12M) [4]. Earnings Forecast - Projected revenues for 2024, 2025, and 2026 are 11.206 billion yuan, 12.478 billion yuan, and 13.931 billion yuan, respectively, with corresponding net profits of 3.071 billion yuan, 3.557 billion yuan, and 4.125 billion yuan [7][8]. - The report anticipates a steady growth rate of approximately 11% for revenue and 10-16% for net profit over the next few years [8].

Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the market by over 15% in the next six months [6][12]. Core Insights - The company reported a revenue of 8.45 billion yuan for the first three quarters of 2024, representing an increase of 11.19% year-on-year, and a net profit attributable to shareholders of 2.69 billion yuan, up 11.73% [3][4]. - The core products, particularly liver disease and cardiovascular medications, showed strong growth, with revenues of 4.28 billion yuan (+20.24%) and 268 million yuan (+11.66%) respectively for the first three quarters [4]. - The company is actively expanding its channel construction, having added over 10,000 new retail outlets through partnerships with major chains [5]. Financial Performance - For Q3 2024, the company achieved a revenue of 2.80 billion yuan (+9.60%) and a net profit of 965 million yuan (+11.73%) [3]. - The overall gross margin for the first three quarters was 45.54%, a decrease of 2.98 percentage points, with liver disease medications showing a gross margin of 70.79% [5][10]. - The forecast for revenue growth is projected at 13.51% for 2024, with net profit expected to reach 3.31 billion yuan, translating to an EPS of 5.49 yuan [6][11]. Product and Market Development - The company has successfully reintroduced the An Gong Niu Huang Wan product, achieving over 100 million yuan in sales, indicating strong demand resilience [4]. - The cosmetics segment also performed well, with a revenue of 525 million yuan (+21.92%) in the first three quarters [4]. - The company is expected to alleviate gross margin pressure through the potential import of raw materials, which may help stabilize costs [5][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported strong performance in liver disease medications and maintained high profitability levels in the third quarter of 2024, with total revenue reaching 8.45 billion yuan, an increase of 11.19% year-on-year, and a net profit attributable to shareholders of 2.687 billion yuan, up 11.73% [3][4] - The pharmaceutical sector showed steady growth, with the pharmaceutical manufacturing industry achieving revenue of 4.612 billion yuan, a growth of 19.71%, while the cosmetics segment also performed well, with revenue of 0.525 billion yuan, an increase of 21.92% [3][4] - The company is focusing on cost reduction and efficiency improvement, maintaining a gross margin of 46.87% despite a decline, while the net profit margin slightly increased to 34.62% [3][4] - The company is enhancing its online and offline sales channels, with significant achievements in e-commerce, including ranking first in sales for liver disease medications on major platforms [4] Financial Forecast and Valuation - The company’s revenue forecast for 2024-2026 has been adjusted to 31.53 billion yuan, 36.19 billion yuan, and 41.42 billion yuan respectively, with corresponding P/E ratios of 46, 40, and 35 times [4] - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 5.23 yuan, 6.00 yuan, and 6.87 yuan respectively [2][4]

Investment Rating - The report maintains a "Cautious Accumulate" rating for the company [6]. Core Views - The company is actively enhancing channel construction, leading to rapid revenue growth from core products, while effectively controlling costs, indicating a potential for sustained performance growth [4]. - For the first three quarters of 2024, the company reported revenue of 8.45 billion yuan (+11.2%) and a net profit attributable to shareholders of 2.687 billion yuan (+11.7%), with Q3 alone contributing 2.8 billion yuan in revenue (+9.6%) and 965 million yuan in net profit (+11.7%), aligning with expectations [4]. - The forecasted EPS for 2024-2026 is set at 5.21, 5.92, and 6.65 yuan respectively, with a target price adjustment to 248.64 yuan based on a 2025 PE of 42X, reflecting the scarcity of core products [4]. Summary by Sections Revenue and Profitability - The company achieved a revenue of 8.45 billion yuan in Q1-3 2024, marking an 11.2% increase year-on-year, with a net profit of 2.687 billion yuan, also up by 11.7% [4]. - The revenue from liver disease medications reached 4.283 billion yuan (+20.2%), with Q3 alone contributing 1.643 billion yuan (+25.3%) [4]. - The gross margin for Q1-3 2024 was 70.8%, a decrease of 7.4 percentage points year-on-year, while the net profit margin slightly decreased by 0.26 percentage points to 32.16% [4]. Cost Control and Efficiency - Despite a rise in raw material costs leading to a gross margin decline, the company has maintained effective cost control, with sales and management expense ratios at 3.93% and 2.69% respectively, both showing year-on-year reductions [4]. - The company continues to focus on cost reduction and efficiency improvements, which are expected to support stable profit growth as brand influence and revenue scale increase [4]. Market Position and Future Outlook - The company is expanding its distribution channels, with over 10,000 new stores added in Q3 and ongoing development of traditional Chinese medicine outlets [4]. - The online sales channels are being strengthened through partnerships with major e-commerce platforms, contributing to overall sales growth [4]. - The anticipated catalysts for growth include exceeding sales expectations for core products and continued channel expansion [4].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 307.50 CNY and a current price of 230.54 CNY [1]. Core Insights - The company's revenue for Q3 2024 is reported at 84.5 billion CNY, reflecting an increase of 11.2% year-on-year, while the net profit attributable to the parent company is 28.0 billion CNY, up by 9.6% [1]. - The core product, Pian Zai Huang, is expected to see a recovery in sales growth, although costs remain under pressure due to rising raw material prices [1]. - The company anticipates significant growth in liver disease medication revenue for the full year, driven by a notable increase in sales during Q3 2024 [1]. Financial Performance Summary - For the first three quarters of 2024, the company reported revenue of 42.8 billion CNY from liver disease medications, with a year-on-year growth of 20.2% [1]. - The gross profit margin for liver disease medications has decreased by 10.8 percentage points year-on-year, primarily due to increased raw material costs [1]. - The company has maintained stable financial indicators, with a projected revenue growth of 15% annually from 2024 to 2026 [1][3]. Revenue Breakdown - The revenue from the cosmetics segment reached 5.3 billion CNY in the first three quarters of 2024, showing a year-on-year increase of 21.9% [1]. - The company’s total revenue projections for 2024, 2025, and 2026 are 11,568 million CNY, 13,302 million CNY, and 15,294 million CNY, respectively, with a consistent growth rate of 15% [3]. Valuation Metrics - The report indicates a price-to-earnings (P/E) ratio of 50 for 2023, decreasing to 33 by 2026, reflecting an expected improvement in earnings [3]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 5.34 CNY, 6.15 CNY, and 7.09 CNY, respectively [3].

证券代码：600436 证券简称：片仔癀 公告编号：2024-046 漳州片仔癀药业股份有限公司 第七届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第二十五次会议于 2024 年 10 月 17 日（星期四）上午 9：00 在公 司片仔癀大厦 24 楼会议室以通讯方式召开。会议通知和议案以专人 送达、电子邮件方式发出。本次会议应参加表决董事 9 人，实际表决 的董事 9 人。会议召开符合《公司法》与《漳州片仔癀药业股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，合法、有效，会 议由董事长林志辉先生主持。经审议，与会董事以通讯方式表决以下 决议： 出席会议的董事 9 票同意，0 票反对，0 票弃权。 报告内容详见公司同日在上海证券交易所网站披露的公告。 本议案已经公司董事会审计委员会 2024 年第八次会议审议通 过，同意相关内容并提交至公司董事会审议。本议案经董事会审议通 过后无需提交至公司股东大会审议。 二、审议通过《公 ...

根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露（2022年修订）》《上市公司行业信息披露指引第六号——医药制造 （2022年修订）》等相关法律法规，漳州片仔癀药业股份有限公司（以 下简称"公司"）现将2024年前三季度主要经营数据披露如下： 证券代码：600436 证券简称：片仔癀 公告编号：2024-048 漳州片仔癀药业股份有限公司 2024年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 公司 2024 年前三季度主营业务分行业情况 | | | | 行业 | 主营业务 | 主营业务 | 毛利率 | 主营业务 收入增长 | 主营业务 成本增长 | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | | 收入 | 成本 | （%） | | | 增减情况 | | | | | | 率（%） | 率（%） | | | 医药 | 461,178.86 | 152,709.23 | 66.89 | 19.71 | 60.08 | 减少 ...